Toxicity evaluation of petroleum blending streams: reproductive and developmental effects of hydrodesulfurized kerosine.
Hydrodesulfurized kerosine (HDS kerosine), applied dermally, was tested for reproductive and developmental toxicity in Sprague-Dawley rats, using a modified OECD Guideline 421, Reproductive/Developmental Toxicity Screening Protocol. A preliminary acute dermal irritancy test demonstrated that dilution of HDS kerosine in either a light (100 Saybolt universal seconds, SUS) or moderate viscosity (340 SUS) USP mineral oil reduced irritation of the neat material comparably. Similar dermal absorption was observed in vitro for neat HDS kerosine or diluted in either of the mineral oils. HDS kerosine diluted to 494 (60%), 330 (40%), or 165 (20%) mg/kg/day in Squibb mineral oil (340 SUS) was applied daily at 1 ml/kg to the shaved backs of rats for 7 wk (premating, mating to d 19 of gestation) to females and 8 wk to males. Dams and litters were sacrificed on postpartum d 4 and males were sacrificed within the following week. HDS kerosine produced slight to moderate skin irritation at the highest dose in both sexes but no apparent maternal, reproductive, or developmental toxicity. No clinical signs of toxicity and no effects on body weight, food consumption, or absolute organ weights were observed. Relative kidney weights were heavier in male rats at the high dose. Skin changes were observed microscopically in male rats in all groups and in females at the high dose. No microscopic changes were observed in reproductive organs of parental animals. There were no differences in mean number of corpora lutea, implantation sites, and live pups per litter, and no gross anomalies were observed. Pups born from treated dams showed comparable body weights and weight gains to controls. The viability index on postpartum d 4 was > or = 93%. In conclusion, the no observable adverse effect level (NOAEL) for HDS kerosine for reproductive and developmental toxicity in rats is 494 mg/kg/d.
Schreiner
C
C
Petroleum Product Stewardship Council, Washington, DC, USA. ceinwen_a_schreiner@email.mobil.com
Bui
Q
Q
Breglia
R
R
Burnett
D
D
Koschier
F
F
Podhasky
P
P
Lapadula
L
L
White
R
R
Feuston
M
M
Krueger
A
A
Rodriquez
S
S
D000287:Administration, Topical; D000818:Animals; D001724:Birth Weight / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003338:Corpus Luteum / Q000187:drug effects; D003876:Dermatitis, Atopic / Q000139:chemically induced*; D005260:Female; D066298:In Vitro Techniques; D007648:Kerosene / Q000032:analysis / Q000633:toxicity*; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D008098:Litter Size / Q000187:drug effects; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008297:Male; D008899:Mineral Oil; D019055:No-Observed-Adverse-Effect Level; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D012098:Reproduction / Q000187:drug effects; D012737:Sex Factors; D012869:Skin Absorption; D013455:Sulfur / Q000032:analysis
D007648:Kerosene; D013455:Sulfur; D008899:Mineral Oil